Thyroid nodules are lumps or growths of the thyroid, usually made up of normal thyroid tissue or fluid. Thyroid nodules are frequently discovered on routine physical examination or unintentionally on imaging tests.
By the age 45, up to half of normal people have thyroid nodules that can be seen on an ultrasound. Fortunately, about 95% of thyroid nodules are benign. The focus of the evaluation at the UCLA Endocrine Center is to help you determine if your nodule contains cancer or not.
Most thyroid nodules do not cause any symptoms. Some thyroid nodules show up as a painless lump in the neck that you can feel or see. Thyroid nodules usually move up and down with swallowing.
When thyroid nodules become large (>4 cm or 1.5 in) they may cause symptoms by pressing on the airway or esophagus. These are also called “compressive symptoms.” Compressive symptoms include:
Sometimes thyroid nodules can produce excess thyroid hormone. Excess thyroid hormone, also called hyperthyroidism, can cause the following signs and symptoms:
At the UCLA Endocrine Center in Los Angeles, multiple layers of evaluation are designed to help you avoid invasive tests and surgery whenever possible. Consultation, ultrasound, and FNA can all be performed in a single visit.
Initial evaluation of a newly discovered thyroid nodule begins with:
An ultrasound is a highly accurate tool to visualize your nodule. There is no associated radiation with ultrasounds and it is non-invasive. Ultrasounds are cost-effective as most patients really don't need any other imaging because the ultrasounds are the best way to look at the thyroid, all present nodules, and the lymph nodes in the neck.
Not all thyroid nodules need a biopsy. Many thyroid nodules we see in our office, we choose not to biopsy because the ultrasound appearance is so reassuring. That is one way to avoid over treatment. For example, nodules that appear completely black on the inside (“anechoic”) are purely cystic, or filled with fluid. The chance of cancer for a cystic nodule is essentially zero and cystic nodules do not require biopsy. There are guidelines from the American Thyroid Association that will help your doctor determine which nodules to biopsy based on their size and how suspicious they look on the ultrasound.
There are certain factors that make a nodule suspicious for thyroid cancer. For example, nodules that do not have smooth borders or have little bright white spots (micro-calcifications) on the ultrasound would make your doctor suspicious that there is a thyroid cancer present. If the nodule appears suspicious on ultrasound and is larger than 1cm, the next step is to do a thyroid biopsy.
Our cytopathologists evaluate over 1000 samples per year, so we are confident in the accuracy of our biopsies. When biopsy does not give a clear answer, we automatically use molecular profiling to refine the diagnosis.
A thyroid biopsy, also called a fine needle aspiration (FNA), uses a small needle to take a little sample of the cells in the thyroid nodule. The possible outcomes from a biopsy are:
Non-diagnostic: Non-diagnostic is a technically failed biopsy. There were not enough cells taken during the biopsy so the cytologist was not able to determine anything. These usually need to be repeated.
Benign: Most thyroid nodule biopsies come back benign, meaning your doctor is highly re-assured that it's not cancerous. Patients can almost always avoid surgery unless the nodule is large and pushing on adjacent structures like the airway.
Indeterminate: Indeterminate means there was enough cells taken during the biopsy, but the cytopathologist was not sure if it is benign or malignant. Indeterminate results occur in about 20% of thyroid biopsies. This is a gray zone and means that the risk of cancer is about 10-30%. These nodules require additional work-up such as a repeat biopsy, molecular marker test, or surgical removal.
Suspicious for Malignancy or Malignant: Results categorized in these two categories are a strong indicator that there is cancer present and usually require surgical removal.
Patients usually wait one week for the cytopathologist to examine the cellular characteristic of the biopsy sample. If your doctor is reassured that it's benign based on the biopsy result, further work-up is stopped and serial ultrasound surveillance is recommended usually once a year.
At UCLA, thyroid nodules with indeterminate biopsies are sent out for an additional molecular marker test. An “indeterminate” biopsy result is the gray zone where the risk of cancer is intermediate (10-30%) but cannot be ignored.
Sometimes the biopsy result is reported as “indeterminate.” This means the cells are not normal, but there are not definite signs of cancer. When biopsies are indeterminate, the risk of thyroid cancer is 15-30%.
In the past, to avoid missing a cancer, we recommended thyroid lobectomy (removal of half of the thyroid) to establish a definitive diagnosis. Now, we use molecular profiling. This refers to commercial DNA or RNA tests made specifically for indeterminate thyroid nodules. If the genetic profile appears benign, patients can avoid surgery and we simply watch the nodule over time with neck ultrasound.
We want to help patients find that perfect balance between under-treatment and over-treatment. The people-gram shows how molecular testing can help patients avoid unnecessary surgery.
Left Path: Before the use of molecular markers, everyone with an indeterminate biopsy went to surgery. Of those who went to surgery, cancer was found in only 25% of those cases (red). 75% of the surgical patients turned out not to have needed surgery at all because their nodules were benign (green).
Right Path: Today, if you have an indeterminate biopsy, you also undergo molecular testing. 50% of patients (green) were categorized as benign from the molecular test and safely avoided surgery. Of the surgical patients who received a suspicious molecular test result (yellow), cancer was found in 50% of those patients (red).
It is very rare that patients end up having cancer because of a false negative test. Still, it is UCLA’s standard of care to have a safety net and follow every patient after molecular testing, regardless of their result. Those patients will get ultrasounds every 12 months to ensure that nodules do not grow or change in appearance.
Thyroid adenomas come in different forms and have different names, but they are benign growths of normal thyroid tissue. These do not require treatment if they are not causing compressive symptoms. If they are not causing symptoms, most of these are watched with neck ultrasound.
Toxic adenomas are thyroid adenomas that secrete excess thyroid hormone.
Thyroid cysts are fluid-filled nodules within the thyroid. Pure thyroid cysts are usually benign (non-cancerous).
Any enlargement of the thyroid gland is referred to as a “goiter.” Goiter can be caused by Hashimoto’s Thyroiditis (an autoimmune disease) and iodine deficiency. These do not require treatment unless the goiter is causing compressive or hyperthyroid symptoms.
A multinodular goiter is an enlarged thyroid gland containing multiple nodules. Most often, these nodules are benign. As above, these only require treatment if you are experiencing compressive or hyperthyroid symptoms, or if one or more of the nodules is suspicious for thyroid cancer.
Thyroid cancer forms when normal thyroid cells undergo genetic changes that cause them to grow in an abnormal way. The most common types of thyroid cancer (papillary and follicular) are typically less aggressive than other cancers. With proper
There are multiple types of thyroid cancer:
Papillary thyroid cancer (PTC) is the most common type of thyroid cancer, making up approximately 80% of all thyroid cancers. Papillary cancer tends to grow slowly and may spread to the lymph nodes in the neck, but still usually has an excellent prognosis. Most patients with papillary thyroid cancer can be successfully treated with a thorough initial operation, and some patients may require additional treatment with radioactive iodine. Most people are cured (over 95%) and have a normal life expectancy.
Follicular thyroid cancer (FTC) is the second most common type of thyroid cancer, making up 10-15% of all thyroid cancers. It may spread to the lymph nodes in the neck, and is also more likely than papillary thyroid cancer to spread through the blood stream to distant areas (such as the lungs). The prognosis for follicular thyroid cancer remains very good – over 90% of patients are cured.
Hurthle cell cancer is a rare type of follicular thyroid cancer that has many pink-staining cells (so-called oncocytes or Hurthle cells). The pathologist will look for signs of cancer cells invading into surrounding blood vessels or breaking outside of the thyroid, which may predict that the cancer will behave more aggressively.
Poorly differentiated and anaplastic (also known as undifferentiated) thyroid cancer means that the cancer cells do not look or behave like normal thyroid cells. Patients usually present with a rapidly growing neck mass. These are very rare types of thyroid cancer, and occur in less than 2% of cases. Unfortunately, they tend to be very aggressive and not responsive to treatment. Management of these cancers involves a multi-disciplinary team with surgeons, endocrinologists, and medical oncologists. At UCLA, these patients may be treated with recently approved targeted therapies, immunotherapy, or clinical trials.
Medullary thyroid cancer (MTC) makes up 5-10% of all thyroid cancer cases. It is often associated with hereditary conditions (MEN-2), and all patients should undergo genetic testing for a RET gene mutation. If a mutation is found, then the patient’s family members may be at risk for medullary thyroid cancer. In addition, new targeted therapies are available for RET-mutated MTC.
Phone: 310-267-7838
Larger image >
Larger image of people-gram >